MX2014015195A - Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos. - Google Patents

Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos.

Info

Publication number
MX2014015195A
MX2014015195A MX2014015195A MX2014015195A MX2014015195A MX 2014015195 A MX2014015195 A MX 2014015195A MX 2014015195 A MX2014015195 A MX 2014015195A MX 2014015195 A MX2014015195 A MX 2014015195A MX 2014015195 A MX2014015195 A MX 2014015195A
Authority
MX
Mexico
Prior art keywords
dual receptor
binding proteins
receptor antagonistic
antagonistic antigen
antibodies
Prior art date
Application number
MX2014015195A
Other languages
English (en)
Inventor
Qing Chen
Huiquan Han
Xiaolan Zhou
Mei-Mei Tsai
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2014015195A publication Critical patent/MX2014015195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta descripción se refiere a proteínas fijadoras de antígeno del receptor de acción dual antagonista, por ejemplo anticuerpos y método para utilizar el anticuerpo de receptor de acción dual para el tratamiento de enfermedades patológicas. El anticuerpo del receptor de acción dual puede comprender un anticuerpo para receptores ActRII y también puede utilizarse para tratar una condición patológica. Las condiciones patológicas pueden comprender enfermedades de desgaste muscular o cualquier enfermedad que requiera la estimulación del crecimiento muscular.
MX2014015195A 2012-06-11 2013-06-11 Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos. MX2014015195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658237P 2012-06-11 2012-06-11
PCT/US2013/045245 WO2013188448A2 (en) 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2014015195A true MX2014015195A (es) 2015-02-17

Family

ID=49758865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015195A MX2014015195A (es) 2012-06-11 2013-06-11 Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos.

Country Status (21)

Country Link
US (4) US9453080B2 (es)
EP (3) EP3498857A1 (es)
JP (1) JP2015525230A (es)
KR (1) KR20150030706A (es)
CN (1) CN104540961A (es)
AU (1) AU2013274347B2 (es)
BR (1) BR112014031028A2 (es)
CA (1) CA2877669A1 (es)
CL (1) CL2014003372A1 (es)
CO (1) CO7240399A2 (es)
EA (1) EA201492282A1 (es)
HK (1) HK1208499A1 (es)
IL (1) IL236133A0 (es)
MA (1) MA37761A1 (es)
MX (1) MX2014015195A (es)
NZ (1) NZ703724A (es)
PE (1) PE20150642A1 (es)
PH (1) PH12014502754A1 (es)
SG (2) SG10201610356YA (es)
TN (2) TN2015000448A1 (es)
WO (1) WO2013188448A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104540961A (zh) 2012-06-11 2015-04-22 安姆根公司 双重受体拮抗性抗原结合蛋白及其用途
CN108409856B (zh) 2012-09-13 2022-03-04 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
US20170260275A1 (en) * 2014-12-08 2017-09-14 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
GB201500464D0 (en) * 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
CA3014197A1 (en) * 2016-02-22 2017-08-31 Ravindra Kumar Actrii antagonists for use in increasing immune activity
JP6987072B2 (ja) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用
EP3538128A4 (en) 2016-11-10 2020-07-22 Keros Therapeutics, Inc. ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
WO2018162931A1 (en) * 2017-03-10 2018-09-13 Ucl Business Plc Method relating to myostatin pathway inhibition
WO2018183376A1 (en) * 2017-03-28 2018-10-04 Rigel Pharmaceuticals, Inc. Acvr2a-specific antibody and method of use thereof
AU2018364668B2 (en) 2017-11-09 2024-05-30 Keros Therapeutics, Inc. Activin receptor type lla variants and methods of use thereof
CN112292144A (zh) 2018-01-12 2021-01-29 科乐斯疗法公司 激活素受体iib型变体及其使用方法
US20220242956A1 (en) * 2019-05-30 2022-08-04 Acceleron Pharma Inc. Actrii-binding proteins and uses thereof
EP4121088A4 (en) * 2020-03-20 2024-07-03 Keros Therapeutics Inc METHODS OF USING ACTIVIN TYPE IIB RECEPTOR VARIANTS
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2003533187A (ja) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
NZ604818A (en) 2008-11-26 2014-07-25 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
ES2655877T3 (es) * 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
KR20140108562A (ko) 2011-12-19 2014-09-11 암젠 인코퍼레이티드 변이체 액티빈 수용체 폴리펩티드 단독 또는 화학 치료법과의 결합, 및 그들의 용도
CN104540961A (zh) * 2012-06-11 2015-04-22 安姆根公司 双重受体拮抗性抗原结合蛋白及其用途
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置

Also Published As

Publication number Publication date
WO2013188448A3 (en) 2014-04-10
EP3498857A1 (en) 2019-06-19
EP2859114A2 (en) 2015-04-15
MA37761A1 (fr) 2017-09-29
IL236133A0 (en) 2015-01-29
CA2877669A1 (en) 2013-12-19
WO2013188448A2 (en) 2013-12-19
HK1208499A1 (en) 2016-03-04
SG11201408228QA (en) 2015-01-29
AU2013274347A1 (en) 2015-02-05
SG10201610356YA (en) 2017-01-27
EP3540070A1 (en) 2019-09-18
JP2015525230A (ja) 2015-09-03
US20170107288A1 (en) 2017-04-20
US10266598B2 (en) 2019-04-23
TN2015000448A1 (en) 2017-04-06
EP2859114A4 (en) 2016-08-03
EA201492282A1 (ru) 2015-07-30
WO2013188448A8 (en) 2014-05-08
US20190256605A1 (en) 2019-08-22
US20210340262A1 (en) 2021-11-04
AU2013274347B2 (en) 2018-03-08
CO7240399A2 (es) 2015-04-17
US20150152194A1 (en) 2015-06-04
US10981999B2 (en) 2021-04-20
CL2014003372A1 (es) 2015-04-10
KR20150030706A (ko) 2015-03-20
NZ703724A (en) 2017-06-30
PH12014502754A1 (en) 2015-03-02
CN104540961A (zh) 2015-04-22
BR112014031028A2 (pt) 2017-08-15
US9453080B2 (en) 2016-09-27
EP2859114B1 (en) 2019-05-15
PE20150642A1 (es) 2015-05-26
TN2014000513A1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
MX2020013062A (es) Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso.
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
PH12017501522A1 (en) Antibodies to tau and uses thereof
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
MY201478A (en) Antibodies and assays for detection of folate receptor 1
EP3528833A4 (en) METHOD FOR TREATMENT OF MUSCLE WASTE AND BONE DISEASE USING NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS
UA114277C2 (uk) Антиангіогенна терапія для лікування раку яєчника
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
EA201990778A1 (ru) Анти-il-33 антитела и их применение
PH12016501366A1 (en) Novel anti-baff antibodies
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MX2020003503A (es) Proteinas de union al antigeno del receptor de oncostatina m.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
EA201490623A1 (ru) Антагонисты толл-подобного рецептора 3 для лечения метаболических и сердечно-сосудистых заболеваний
MX2017010306A (es) Bloqueadores del receptor de la hormona del crecimiento en la prevencion y tratamiento de enfermedades.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
CR20150030A (es) Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения